Acro Biomedical Co., Ltd. (ACBM) Stock Price & Analysis
Acro Biomedical Co., Ltd. (ACBM) rose 0.00% to USD 0.03 as of June 10, 2026 at 01:47 UTC, according to Nexqual real-time market data.
ACBM last closed at USD 0.03; the session ranged USD 0.03–0.03 on volume of 66 shares. Market capitalization is $1.56M, with a 52-week range of USD 0–0.1 (PNK). Source: Nexqual, June 10, 2026 at 01:47 UTC.
Key Statistics (as of June 10, 2026 at 01:47 UTC)
| Price | USD 0.03 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.03 |
| Open | USD 0.03 |
| Day Range | USD 0.03 – 0.03 |
| 52-Week Range | USD 0 – 0.1 |
| Volume | 66 shares |
| Market Cap | $1.56M |
| Exchange | PNK |
Technical Analysis (ACBM)
Nexqual's technical model rates ACBM "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 01:47 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0.03) |
| MACD | 0 (negative) |
Analyst Ratings (ACBM)
Wall Street analysts rate ACBM "None", per Nexqual as of June 10, 2026 at 01:47 UTC.
| Consensus Rating | None |
|---|
Earnings (ACBM)
Source: Nexqual, June 10, 2026 at 01:47 UTC.
Financials & Fundamentals (ACBM)
| Total Revenue | $193,536 |
|---|---|
| Revenue Growth (YoY) | -85.70% |
| Gross Margin | +6.25% |
| Operating Margin | -38.98% |
| Profit Margin | -192.01% |
| ROE | -37.80% |
| Debt / Equity | 9.09 |
| Current Ratio | 7.89 |
| Total Cash | $911 |
| Total Debt | $72,589 |
| Free Cash Flow | $330,946 |
Source: Nexqual, June 10, 2026 at 01:47 UTC.
Financial Health Score (ACBM)
Nexqual rates Acro Biomedical Co., Ltd.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:47 UTC.
| Growth | Critical — Revenue -86% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $911 cash, no debt |
| Cash Flow | Strong — FCF $331K, 171% margin |
| Efficiency | Critical — ROE -38%, ROA -24.0% |
Ownership (ACBM)
| Insider Ownership | +49.96% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 60.04M |
| Float | 17.76M |
Source: Nexqual, June 10, 2026 at 01:47 UTC.
Leadership (ACBM)
Acro Biomedical Co., Ltd. is led by Yu-Ting Su (age 37), Chairman, CEO, CFO, President & Secretary, per Nexqual as of June 10, 2026 at 01:47 UTC.
| Chairman, CEO, CFO, President & Secretary | Yu-Ting Su (age 37) |
|---|
From Acro Biomedical Co., Ltd.'s Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Acro Biomedical Co., Ltd. engages in the development and marketing of nutritional products in Indiana and internationally.
- It is involved in the development and sale of cordyceps related products, a fungus used in traditional Chinese medicine.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INLB | ITEM 9 LABS CORP | USD 0 | ▲ 0% |
| NMTRQ | 9 Meters Biopharma, Inc. | USD 0 | ▲ 0% |
| AGILQ | AgileThought, Inc. | USD 0 | ▲ 0% |
| PAIOF | PAION AG | USD 0.01 | ▲ 0% |
| CIBH | CIB Marine Bancshares, Inc. | USD 40.86 | ▲ 3.84% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:47 UTC. This page is informational and not investment advice.